These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22848772)

  • 1. Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy.
    Hashim R; Khatib AM; Enwere G; Park JK; Reyburn R; Ali M; Chang NY; Kim DR; Ley B; Thriemer K; Lopez AL; Clemens JD; Deen JL; Shin S; Schaetti C; Hutubessy R; Aguado MT; Kieny MP; Sack D; Obaro S; Shaame AJ; Ali SM; Saleh AA; von Seidlein L; Jiddawi MS
    PLoS Negl Trop Dis; 2012; 6(7):e1743. PubMed ID: 22848772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.
    Trach DD; Cam PD; Ke NT; Rao MR; Dinh D; Hang PV; Hung NV; Canh DG; Thiem VD; Naficy A; Ivanoff B; Svennerholm AM; Holmgren J; Clemens JD
    Bull World Health Organ; 2002; 80(1):2-8. PubMed ID: 11884967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of travellers' diarrhoea by WC/rBS oral cholera vaccine in young, high-risk travellers.
    Torrell JM; Aumatell CM; Ramos SM; Mestre LG; Salas CM
    Vaccine; 2009 Jun; 27(30):4074-7. PubMed ID: 19376179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study.
    Khatib AM; Ali M; von Seidlein L; Kim DR; Hashim R; Reyburn R; Ley B; Thriemer K; Enwere G; Hutubessy R; Aguado MT; Kieny MP; Lopez AL; Wierzba TF; Ali SM; Saleh AA; Mukhopadhyay AK; Clemens J; Jiddawi MS; Deen J
    Lancet Infect Dis; 2012 Nov; 12(11):837-44. PubMed ID: 22954655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of the oral cholera vaccine in pregnancy: Retrospective findings from a subgroup following mass vaccination campaign in Dhaka, Bangladesh.
    Khan AI; Ali M; Chowdhury F; Saha A; Khan IA; Khan A; Akter A; Asaduzzaman M; Islam MT; Kabir A; You YA; Saha NC; Cravioto A; Clemens JD; Qadri F
    Vaccine; 2017 Mar; 35(11):1538-1543. PubMed ID: 28196715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of a killed oral cholera vaccine (Shanchol) in pregnant women in Malawi: an observational cohort study.
    Ali M; Nelson A; Luquero FJ; Azman AS; Debes AK; M'bang'ombe MM; Seyama L; Kachale E; Zuze K; Malichi D; Zulu F; Msyamboza KP; Kabuluzi S; Sack DA
    Lancet Infect Dis; 2017 May; 17(5):538-544. PubMed ID: 28161570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of mass oral cholera vaccination in Beira, Mozambique.
    Lucas ME; Deen JL; von Seidlein L; Wang XY; Ampuero J; Puri M; Ali M; Ansaruzzaman M; Amos J; Macuamule A; Cavailler P; Guerin PJ; Mahoudeau C; Kahozi-Sangwa P; Chaignat CL; Barreto A; Songane FF; Clemens JD
    N Engl J Med; 2005 Feb; 352(8):757-67. PubMed ID: 15728808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.
    Clemens JD; Sack DA; Harris JR; Van Loon F; Chakraborty J; Ahmed F; Rao MR; Khan MR; Yunus M; Huda N
    Lancet; 1990 Feb; 335(8684):270-3. PubMed ID: 1967730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community-based assessment of safety and immunogenicity of the whole cell plus recombinant B subunit (WC/rBS) oral cholera vaccine in Peru.
    Begue RE; Castellares G; Ruiz R; Hayashi KE; Sanchez JL; Gotuzzo E; Oberst RB; Taylor DN; Svennerholm AM
    Vaccine; 1995 May; 13(7):691-4. PubMed ID: 7668039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial.
    Cordero De Los Santos L; Feris-Iglesias J; Aloysia D'Cor N; Midde VJ; Patnaik BN; Thollot Y; Rasuli A; Desauziers E
    Hum Vaccin Immunother; 2018 Jun; 14(6):1403-1411. PubMed ID: 29470934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers.
    Jertborn M; Svennerholm AM; Holmgren J
    Vaccine; 1992; 10(2):130-2. PubMed ID: 1539466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An oral B subunit: whole cell vaccine against cholera.
    Holmgren J; Svennerholm AM; Jertborn M; Clemens J; Sack DA; Salenstedt R; Wigzell H
    Vaccine; 1992; 10(13):911-4. PubMed ID: 1471411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity.
    Clemens JD; Stanton BF; Chakraborty J; Sack DA; Khan MR; Huda S; Ahmed F; Harris JR; Yunus M; Khan MU
    J Infect Dis; 1987 Jan; 155(1):79-85. PubMed ID: 3540139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of a bivalent, killed, whole-cell oral cholera vaccine in pregnant women in Bangladesh: evidence from a randomized placebo-controlled trial.
    Khan AI; Ali M; Lynch J; Kabir A; Excler JL; Khan MA; Islam MT; Akter A; Chowdhury F; Saha A; Khan IA; Desai SN; Kim DR; Saha NC; Singh AP; Clemens JD; Qadri F
    BMC Infect Dis; 2019 May; 19(1):422. PubMed ID: 31092224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of two formulations of oral cholera vaccine comprised of killed whole vibrios and the B subunit of cholera toxin.
    Migasena S; Desakorn V; Suntharasamai P; Pitisuttitham P; Prayurahong B; Supanaranond W; Black RE
    Infect Immun; 1989 Jan; 57(1):117-20. PubMed ID: 2909484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.
    Sur D; Lopez AL; Kanungo S; Paisley A; Manna B; Ali M; Niyogi SK; Park JK; Sarkar B; Puri MK; Kim DR; Deen JL; Holmgren J; Carbis R; Rao R; Nguyen TV; Donner A; Ganguly NK; Nair GB; Bhattacharya SK; Clemens JD
    Lancet; 2009 Nov; 374(9702):1694-702. PubMed ID: 19819004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A safety assessment on adverse reaction of recombinant B-subunit/inactivated whole cell oral cholera vaccine among non-infected population].
    Zhang XP; Chen EF; Lv HK
    Zhongguo Yi Miao He Mian Yi; 2009 Jun; 15(3):255-8. PubMed ID: 20084896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
    Raghava Mohan V; Raj S; Dhingra MS; Aloysia D'Cor N; Singh AP; Saluja T; Kim DR; Midde VJ; Kim Y; Vemula S; Narla SK; Sah B; Ali M
    PLoS One; 2019; 14(6):e0218033. PubMed ID: 31211792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines.
    Russo P; Ligsay AD; Olveda R; Choi SK; Kim DR; Park JY; Park JY; Syed KA; Dey A; Kim YH; Lee SH; Kim J; Chon Y; Digilio L; Kim CW; Excler JL
    Vaccine; 2018 Jul; 36(29):4317-4324. PubMed ID: 29895500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.